-
BioPharma Dive – AI / Data3 weeks agoRoche stops work on experimental SMA drug
In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and...
-
BioPharma Dive – AI / Data3 weeks agoNovartis pays $2B to land a startup’s breast cancer drug
Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to...
-
BioPharma Dive – AI / Data3 weeks agoRhythm obesity drug wins broader use from FDA
Imcivree’s clearance in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.
-
BioPharma Dive – AI / Data3 weeks agoNovo uses FDA voucher to win speedy approval of higher-dose Wegovy
The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli Lilly.
-
BioPharma Dive – AI / Data3 weeks agoLilly’s three-pronged obesity drug hits goal in large diabetes trial
Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a sign it might be similarly impactful...
-
BioPharma Dive – AI / Data3 weeks agoPfizer aims for wider use of PARP drug in prostate cancer with new data
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should justify use in earlier lines...
-
BioPharma Dive – AI / Data3 weeks agoA biotech VC sees early signs of a turnaround for startups
After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.
-
BioPharma Dive – AI / Data3 weeks agoAstraZeneca to boost cell therapy capabilities with new China investment
The planned Shanghai facility extends a yearslong push into the field and will support CAR-T therapies AstraZeneca is making for autoimmune disease and cancer.
-
BioPharma Dive – AI / Data3 weeks agoRBC: Revolution, Xenon, Arrowhead among top takeover targets
As part of a larger review, analyst Leonid Timashev identified 13 companies that could see deal interest as well as more than half a dozen poised...
-
BioPharma Dive – AI / Data3 weeks agoJ&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J&J has said the new drug,...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
